MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases
July 15 2015 - 8:30AM
Business Wire
The Medical University of South Carolina and Bristol-Myers
Squibb Company (NYSE: BMY) today announced that they have entered
into a translational research collaboration focused on fibrotic
diseases, including scleroderma, renal fibrosis and idiopathic
pulmonary fibrosis. The agreement includes studies designed to
improve the mechanistic understanding of fibrosis, explore patient
segmentation based on disease characteristics and/or biomarker
approaches and predictors of disease progression.
“Bristol-Myers Squibb’s collaboration with MUSC further
strengthens and advances our Discovery research efforts in fibrotic
diseases, a strategic area of focus for the company,” said Carl
Decicco, Ph.D., Head of Discovery, R&D, Bristol-Myers Squibb.
“MUSC brings substantial expertise in translational research and
drug discovery related to fibrotic diseases including access to
patient derived disease tissue samples that will help us accelerate
the application of scientific knowledge to potential new treatment
approaches for patients.”
“This is an exciting opportunity with the potential to make a
significant impact in fibrotic diseases and in patients’ lives with
these debilitating diseases,” said Karen Lackey, MUSC Center for
Therapeutic Discovery and Development executive director and
pharmacy associate professor. “Our goal with translational research
is to shorten the timeline in getting patients the medications and
treatments they need. We have unparalleled expertise in fibrosis
research at MUSC, and this collaboration with a leader like
Bristol-Myers Squibb in discovery and development of medications is
going to take that foundational work to the next level.”
Bristol-Myers Squibb and MUSC are committed to addressing the
unmet need in fibrotic diseases that are characterized by the
formation of excess fibrous connective tissue in an organ or
tissue, by identifying novel medicines to halt or slow disease
progression. Among the assets in Bristol-Myers Squibb’s fibrosis
portfolio are BMS-986020, a lysophosphatidic acid 1 (LPA1) receptor
antagonist in Phase 2 development for the treatment of idiopathic
pulmonary fibrosis (IPF), and a CCR2/5 dual antagonist in Phase 2
development for diabetic kidney disease. In addition, in
November 2014, Bristol-Myers Squibb and Galecto Biotech AB
announced an agreement that provides Bristol-Myers Squibb the
exclusive option to acquire Galecto Biotech AB and gain worldwide
rights to its lead asset TD139, a novel inhaled inhibitor of
galectin-3 in Phase 1 development for the treatment of IPF and
other pulmonary fibrotic conditions. Bristol-Myers Squibb and the
California Institute for Biomedical Research (Calibr) also
announced a worldwide research collaboration in January 2015 to
develop novel small molecule anti-fibrotic therapies, and an
exclusive license agreement that allows Bristol-Myers Squibb to
develop, manufacture and commercialize Calibr’s preclinical
compounds resulting from the collaboration.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information, please visit www.bms.com or follow us on Twitter at
http://twitter.com/bmsnews.
About MUSC
Founded in 1824 in Charleston, The Medical University of South
Carolina is the oldest medical school in the South. Today, MUSC
continues the tradition of excellence in education, research, and
patient care. MUSC educates and trains more than 3,000 students and
residents, and has nearly 13,000 employees,
including approximately 1,500 faculty members. As the
largest non-federal employer in Charleston, the university and its
affiliates have collective annual budgets in excess of $1.7
billion. MUSC operates a 750-bed medical center, which
includes a nationally recognized Children's Hospital, the Ashley
River Tower (cardiovascular, digestive disease, and surgical
oncology), Hollings Cancer Center (one of 66 National Cancer
Institute designated centers) Level I Trauma Center and
Institute of Psychiatry. For more information on academic
information or clinical services, visit www.musc.edu. For more
information on hospital patient services,
visit www.muschealth.org.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee
that the investigational compounds discussed in this release will
be successfully developed or approved for any of the indications
described in this release. Forward-looking statements in this press
release should be evaluated together with the many uncertainties
that affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2014 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
Contacts
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150715005767/en/
Bristol-Myers SquibbMedia:Sarah Koenig,
609-252-4145, sarah.koenig@bms.comInvestors:Ranya Dajani,
609-252-5330, ranya.dajani@bms.comMUSCMedia:Heather Woolwine, 843-792-7669,
woolwinh@musc.edu
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024